Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStopping Wegovy doesn't trigger withdrawal in the clinical sense, but most people do notice changes when semaglutide leaves their system. Appetite returns, often sharply. Weight can begin to creep back. Understanding this sequence before you stop makes the difference between a planned pause and an unwelcome surprise. These are prescription-only medicines, and any decision to stop or reduce your dose is one to make with your prescriber, not unilaterally.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy is a once-weekly injection, and semaglutide has a half-life of roughly seven days. That means it takes several weeks for the medicine to clear your system entirely after your final dose. During those first one to two weeks you may not notice much difference. The drug is still circulating, still occupying GLP-1 receptors, still slowing gastric emptying to some degree.
By weeks three and four, most of the pharmacological effect has gone. That's when the changes tend to become noticeable. Your stomach empties at its pre-treatment speed. The brain signals that were dampening hunger start reasserting themselves. People describe it as hunger returning with a kind of urgency they hadn't felt in months. The NHS patient information for semaglutide is a useful reference point for understanding how the medicine works and what to expect when it's discontinued — it's worth reading before you stop.
There's nothing happening here that is medically dangerous in itself. Semaglutide doesn't create dependence, and stopping doesn't cause the physical symptoms you'd associate with stopping certain other medicines. If you want to understand what the transition period can feel like in more detail, our guide to wegovy withdrawal symptoms covers what people commonly report in the weeks after their last injection. What you're experiencing is simply your own biology reasserting itself.
This is the part most people are unprepared for. Clinical evidence is fairly consistent: without the behavioural changes that semaglutide made easier to sustain, weight returns. The STEP 1 trial, published in the New England Journal of Medicine, found that participants who stopped semaglutide regained most of their lost weight within a year when treatment wasn't continued alongside structured lifestyle support.
That's not a failure of the medicine, it's the nature of obesity as a chronic condition. Semaglutide works while you take it. The underlying biology that drives appetite and fat storage doesn't change permanently because you used it for twelve or eighteen months. Obesity UK has written clearly about this, and it's the same framing that NICE uses in its clinical guidance.
The practical upshot: stopping should ideally come with a plan. What habits have you built during treatment? Is your relationship with food different now? Have you spoken to your prescriber about whether a pause, a dose reduction, or a structured stopping point makes more sense for you than a sharp end? These are the real questions to work through. You can read more about the broader landscape of semaglutide treatment if you're weighing options.
For many people, stopping Wegovy actually brings relief from the gastrointestinal side effects that can accompany treatment. Nausea, reflux, and changes in bowel habit often improve within a week or two of stopping. That's one reason some people choose to stop without fully considering the appetite rebound, they feel better quickly, and assume everything is settling positively.
It is. But the fuller picture only becomes clear a few weeks later. This is why the stopping period is worth logging, particularly in the first month. If you were keeping a food diary or tracking your weight during treatment, keeping that habit through the transition gives you real data to bring back to your prescriber if needed.
Side effects that were present during treatment (including any gastrointestinal discomfort) should be discussed with your prescriber before stopping, not used as a sole reason to stop abruptly. Some of those symptoms are manageable with dose adjustments rather than full discontinuation. Our Wegovy treatment guide covers the side-effect profile in full if you want to read about specific symptoms before your next prescriber conversation. For anything involving bloating or gas on Wegovy, there's separate guidance that may be useful too.
Stopping Wegovy isn't the end of the conversation about weight management, it's often the beginning of a different one. Whether you've completed a planned course, hit a point where supply or cost has become a factor (the process for accessing Wegovy privately covers what that currently looks like), or your prescriber has suggested a pause for clinical reasons, the question is always: what's the structure going forward?
Some people transition to a different medicine. Some maintain with lifestyle alone. Some restart after a break. Your prescriber is the right person to map that with you, not based on what worked for someone else, but on your specific history, weight trajectory and health picture. Knowing what not to take alongside any medicine you transition to matters too; our page on interactions to be aware of with Wegovy is a useful reference.
The question of what a managed, clinically supervised stopping process looks like is exactly the kind of thing our prescribers work through with patients. If you're considering stopping, or have already stopped and want a clinical view on what comes next, a free consultation with our team is the place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.